Figure 3.

TTI-4242 improves tumor control in mice treated with αPD-1 therapy. (a) Experimental scheme; B16.F10 tumor-bearing mice received 200μg αPD-1 twice a week for three weeks and/or schweinfurthin (30 mg/kg TTI-4242) for five consecutive days. Control mice received 200μg rat IgG or an equivalent volume of vehicle. Once tumors became palpable (~ 20mm³), mice were treated with (b) IgG and vehicle, (c) αPD-1 and vehicle, (d) IgG and TTI-4242, (e) αPD-1 and TTI-4242. Days 10 and 20 are indicated with long- and short-dashed lines. N = 6–9/group; p values determined by mixed linear models and shown for pairwise comparisons to αPD-1 + TTI-4242. (f) Kaplan-meier survival analysis. Arrow indicates the day of challenge (day 42). N = 6–9/group; p values determined by log rank test; pairwise comparisons between αPD-1 + TTI-4242 and all other groups: ** p < 0.01. (g) The percentage of mice tumor-free (no palpable or visually apparent tumor) in each treatment group. The experiment was terminated at 100 days post treatment initiation at which point all surviving mice were tumor free.